LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

Search

Gossamer Bio Inc

Închisă

SectorSănătate

2.46 -3.53

Rezumat

Modificarea prețului

24h

Curent

Minim

2.45

Maxim

2.64

Indicatori cheie

By Trading Economics

Venit

-1.6M

-38M

Vânzări

1.6M

11M

Marjă de profit

-333.127

Angajați

144

EBITDA

-1.8M

-35M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+315.02% upside

Statistici piață

By TradingEconomics

Capitalizare de piață

42M

537M

Deschiderea anterioară

5.99

Închiderea anterioară

2.46

Sentimentul știrilor

By Acuity

60%

40%

331 / 372 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

Gossamer Bio Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

27 aug. 2025, 22:51 UTC

Câștiguri

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

27 aug. 2025, 23:57 UTC

Câștiguri

Trip.com Group 1H Rev $4.01B

27 aug. 2025, 23:57 UTC

Câștiguri

Trip.com Group 1H Adj EPS $1.84

27 aug. 2025, 23:57 UTC

Câștiguri

Trip.com Group 1H EPS $1.82

27 aug. 2025, 23:50 UTC

Market Talk

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

27 aug. 2025, 23:39 UTC

Câștiguri

Correction to Nvidia Earnings Article -- WSJ

27 aug. 2025, 22:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27 aug. 2025, 22:59 UTC

Market Talk

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

27 aug. 2025, 22:58 UTC

Câștiguri

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

27 aug. 2025, 22:57 UTC

Câștiguri

South32 FY Free Cash Flow $192 Million

27 aug. 2025, 22:56 UTC

Câștiguri

South32 FY Total Capital Expenditure $1.35 Billion

27 aug. 2025, 22:56 UTC

Câștiguri

South32 FY Capital Expenditure $963 Million, Excluding EAIs

27 aug. 2025, 22:55 UTC

Câștiguri

South32 Net Cash $123 Million at June 30

27 aug. 2025, 22:54 UTC

Câștiguri

South32: Focused on Maintaining Strong Operating Momentum

27 aug. 2025, 22:53 UTC

Câștiguri

South32: $144 Million Remains to be Returned to Shareholders Under Program

27 aug. 2025, 22:53 UTC

Câștiguri

South32 Extends Capital Management Program for 12 Months

27 aug. 2025, 22:52 UTC

Câștiguri

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

27 aug. 2025, 22:51 UTC

Câștiguri

South32 FY Revenue $5.78 Billion, Up 17% On-Year

27 aug. 2025, 22:51 UTC

Câștiguri

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

27 aug. 2025, 22:50 UTC

Câștiguri

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

27 aug. 2025, 22:50 UTC

Câștiguri

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

27 aug. 2025, 22:45 UTC

Câștiguri

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

27 aug. 2025, 22:44 UTC

Câștiguri

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

27 aug. 2025, 22:44 UTC

Câștiguri

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

27 aug. 2025, 22:43 UTC

Câștiguri

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

27 aug. 2025, 22:43 UTC

Câștiguri

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

27 aug. 2025, 22:42 UTC

Câștiguri

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

27 aug. 2025, 22:42 UTC

Câștiguri

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

27 aug. 2025, 22:40 UTC

Câștiguri

Sandfire Resources Net Debt $123 Million at June 30

27 aug. 2025, 22:40 UTC

Câștiguri

Sandfire Resources FY Underlying Ebitda $527.7 Million

Comparație

Modificare preț

Gossamer Bio Inc Așteptări

Obiectiv de preț

By TipRanks

315.02% sus

Prognoză pe 12 luni

Medie 10.5 USD  315.02%

Maxim 15 USD

Minim 6 USD

În baza a 4 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruGossamer Bio Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

4 ratings

4

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

1.06 / 1.23Suport & Rezistență

Termen scurt

Weak Bullish Evidence

Termen mediu

Weak Bearish Evidence

Termen lung

Bullish Evidence

Sentiment

By Acuity

331 / 372 Clasament în Sănătate

Sentimentul știrilor

Evidențe de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.